Navigation Links
Magnesium Sulfate Reduces Threat of Cerebral Palsy
Date:8/27/2008

Compound given to women at risk of preterm birth cuts risk in half, study finds

WEDNESDAY, Aug. 27 (HealthDay News) -- Magnesium sulfate, given to mothers at risk of preterm delivery, cut the rate of cerebral palsy in their babies by nearly half, a new study found.

"If deemed to be at high or immediate risk of delivery prior to 32 weeks, women and their doctors should consider using magnesium sulfate to prevent their child from having cerebral palsy," said study lead author Dr. Dwight J. Rouse, a professor of obstetrics and gynecology at the University of Alabama at Birmingham.

The findings are published in the Aug. 28 issue of the New England Journal of Medicine.

But in an editorial accompanying the study, other experts called for caution and more study before routinely recommending the treatment to prevent cerebral palsy.

In the study, the largest of its kind, Rouse and his colleagues randomly assigned 2,241 women at risk of delivering early -- between 24 and 31 weeks -- to receive either magnesium sulfate or a placebo. (Babies born after 37 to 42 weeks of pregnancy are considered full term, according to the March of Dimes.) The magnesium sulfate was given intravenously as the women entered labor as a 6-gram dose followed by a constant infusion of 2 grams per hour until either 12 hours had passed, labor had subsided, or they had given birth.

The researchers then compared infants born to each group of mothers to see if there were differences in the rates of death or the occurrence of cerebral palsy.

Cerebral palsy, marked by abnormal movement control and postures that cause limited activity, is caused by damage or dysfunction to the developing fetal or infant brain. Preterm birth is itself a risk factor for the condition. About one third of cerebral palsy cases are associated with preterm birth.

In past studies, magnesium sulfate hasn't borne out as an effective treatment for delay of early labor. But it has proven effective for treatment of maternal high blood pressure associated with pregnancy, Rouse said.

And some previous research had found magnesium sulfate effective for reducing the risk of cerebral palsy, but other studies had been inconclusive. So, Rouse and his colleagues embarked on this large, more comprehensive study.

They found no significant differences in the proportion of deaths between the magnesium sulfate group and the placebo group. But they did find that moderate or severe cerebral palsy was diagnosed in just 1.9 percent of the group treated with magnesium sulfate, compared to 3.5 percent in the placebo group.

Rouse said it's not known for certain how the compound may work. But, he said, it may "stabilize the vessels in the vulnerable preterm brain," protect against damage from lack of oxygen, and guard against injury caused by swelling and inflammation.

"Our findings are applicable only to early preterm birth," he added. "We define high risk as threatening delivery prior to 32 weeks."

Dr. William Zinser is a pediatric neurologist at Children's Medical Center, Dallas, and an associate professor of pediatric neurology at the University of Texas Southwestern Medical Center. He said, "It's too early to know if magnesium sulfate has an overall effect on the incidence rate of cerebral palsy."

Zinser reviewed the study but was not involved with it. "More research needs to be done, certainly," he said.

Rouse said women at risk for preterm birth should discuss the potential use of magnesium sulfate with their doctors.

More information

To learn more about preterm birth, visit the March of Dimes.



SOURCES: Dwight J. Rouse, M.D., professor of obstetrics and gynecology, University of Alabama at Birmingham; William Zinser, M.D., pediatric neurologist, Children's Medical Center, Dallas, and associate professor of pediatric neurology, University of Texas Southwestern Medical Center at Dallas; Aug. 28, 2008, New England Journal of Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Magnesium May Lower Risk for Some Strokes in Male Smokers
2. Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
3. ETHEX Corporation Voluntarily Recalls a Single Lot of Morphine Sulfate 60 mg Extended Release Tablets Due to the Potential for Oversized Tablets
4. Roxane Laboratories, Inc. Announces the Approval of Morphine Sulfate Tablets and Oral Solution
5. New study: Pine bark reduces perimenopausal symptoms
6. Different method of evaluating the urinary tract system reduces radiation dose
7. Saline Reduces Mortality for Brain Injury Patients
8. New study: Pine bark extract reduces ADHD symptoms in children
9. Radiation therapy technique reduces length of prostate cancer treatment
10. Radiation therapy technique reduces length of prostate cancer treatment
11. MR spectroscopy identifies breast cancer, reduces biopsies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ODH, Inc.™ ... Care Summit, February 27-28 at the Sheraton Pentagon City Hotel in Arlington, VA. ODH’s ... PerformCARE to use behavioral health analytics to improve Medicaid population health management. , ODH ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... newly designed TaskMate Go. Core benefits and advantages built into the home office ... stylish, functional look and feel. Ability to gain the benefits embedded in the ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis ... University of Pittsburgh points to eight genes that may explain why susceptibility to one ... the results of a study published today in the journal npj Schizophrenia. , ...
(Date:2/24/2017)... ... 2017 , ... With millions of Americans and people worldwide ... all are aware of our options and are empowered with strength and information ... of its newest edition of "Vision and Hearing" in USA Today, that will ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University Institute for Palliative ... in or interested in palliative care education and research. The Symposium, “Innovate. Investigate. ... County San Diego on Sept. 28 and 29, 2017, on the campus of California ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... YORK , Feb. 23, 2017  This report ... Thousand by the following Products: Intermediates, ... in the report include Pharmaceuticals, and Agrochemicals. The report ... Japan , Europe , and ... for the period 2015 through 2022. Also, a six-year ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
(Date:2/23/2017)... -- Genesis Healthcare Services has merged with Hospice Cloud, a ... Bill Monast , President and CEO of Hospice Cloud ... , executives with Home Health Depot, Inc., the parent ... This acquisition helps Hospice Cloud maintain its position as ... equipment (DME) solutions for the hospice industry. Nathan ...
Breaking Medicine Technology: